SalvaRx Group Plc Company Profile (LON:3LEG)

About SalvaRx Group Plc (LON:3LEG)

SalvaRx Group Plc logoSalvaRx Group plc, formerly 3Legs Resources plc, is an investing company. The Company is engaged in drug discovery and development, focused on immune-oncology. The Company's segment is appraisal of investment targets meeting the Company's investment policy. The Company is focused on evaluation and assessment of investment opportunities in line with the investment policy. Its product is IMM60. It expects the study to evaluate approximately three treatment groups: a control arm using the standard of care (an anti-programmed death (PD)-1 therapy), a trial arm using iOX Therapeutics Ltd's drug (IMM60), and a third arm that will test the combination of IMM60 and an anti-PD1 therapy. 3Legs Management Services US LLC is the subsidiary of the Company.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:3LEG
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: GBX 1.19
  • 200 Day Moving Avg: GBX 0.54
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00

Frequently Asked Questions for SalvaRx Group Plc (LON:3LEG)

What is SalvaRx Group Plc's stock symbol?

SalvaRx Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "3LEG."

Who are some of SalvaRx Group Plc's key competitors?

How do I buy SalvaRx Group Plc stock?

Shares of SalvaRx Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of SalvaRx Group Plc stock cost?

One share of SalvaRx Group Plc stock can currently be purchased for approximately GBX 0.32.

Analyst Ratings

Consensus Ratings for SalvaRx Group Plc (LON:3LEG) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for SalvaRx Group Plc (LON:3LEG)
DateFirmActionRatingPrice TargetDetails
2/2/2016Northland SecuritiesReiterated RatingCorporateView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for SalvaRx Group Plc (LON:3LEG)
No earnings announcements for this company have been tracked by


Earnings Estimates for SalvaRx Group Plc (LON:3LEG)
Current Year EPS Consensus Estimate: $-3.00 EPS


Dividend History for SalvaRx Group Plc (LON:3LEG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for SalvaRx Group Plc (LON:3LEG)
No insider trades for this company have been tracked by


Headline Trends for SalvaRx Group Plc (LON:3LEG)
Latest Headlines for SalvaRx Group Plc (LON:3LEG)


Social activity is not available for this stock.


SalvaRx Group Plc (3LEG) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff